Concepts (169)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ivermectin | 1 | 2021 | 1 | 0.770 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 43 | 0.740 |
Why?
|
| Tuberculosis | 5 | 2022 | 543 | 0.670 |
Why?
|
| Antitubercular Agents | 4 | 2017 | 322 | 0.570 |
Why?
|
| Coinfection | 4 | 2023 | 276 | 0.530 |
Why?
|
| Pneumococcal Infections | 5 | 2019 | 299 | 0.510 |
Why?
|
| Infant | 20 | 2024 | 2244 | 0.500 |
Why?
|
| Humans | 35 | 2024 | 14537 | 0.480 |
Why?
|
| South Africa | 25 | 2024 | 7596 | 0.460 |
Why?
|
| Child | 15 | 2024 | 2242 | 0.440 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2011 | 195 | 0.420 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 3 | 2011 | 226 | 0.410 |
Why?
|
| Child Health Services | 1 | 2011 | 35 | 0.380 |
Why?
|
| Child, Preschool | 14 | 2024 | 1748 | 0.370 |
Why?
|
| Sentinel Surveillance | 2 | 2024 | 115 | 0.370 |
Why?
|
| Whooping Cough | 2 | 2023 | 36 | 0.360 |
Why?
|
| HIV Infections | 13 | 2022 | 5097 | 0.360 |
Why?
|
| Serogroup | 4 | 2019 | 150 | 0.350 |
Why?
|
| Neonatal Sepsis | 2 | 2020 | 29 | 0.330 |
Why?
|
| Infant, Newborn | 12 | 2024 | 1479 | 0.330 |
Why?
|
| Meningitis, Bacterial | 2 | 2022 | 38 | 0.320 |
Why?
|
| Streptococcus pneumoniae | 4 | 2022 | 336 | 0.310 |
Why?
|
| Female | 20 | 2024 | 9103 | 0.290 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 127 | 0.280 |
Why?
|
| Male | 16 | 2024 | 6754 | 0.260 |
Why?
|
| Bordetella pertussis | 2 | 2023 | 29 | 0.260 |
Why?
|
| Pneumococcal Vaccines | 4 | 2017 | 278 | 0.250 |
Why?
|
| Neisseria meningitidis | 2 | 2022 | 36 | 0.240 |
Why?
|
| Evidence-Based Medicine | 2 | 2021 | 34 | 0.230 |
Why?
|
| Antibodies, Bacterial | 2 | 2015 | 153 | 0.230 |
Why?
|
| Hospitalization | 2 | 2024 | 418 | 0.230 |
Why?
|
| Infection Control | 2 | 2021 | 31 | 0.220 |
Why?
|
| Child, Hospitalized | 2 | 2021 | 26 | 0.220 |
Why?
|
| Streptococcus agalactiae | 2 | 2015 | 202 | 0.220 |
Why?
|
| Streptococcal Infections | 2 | 2015 | 184 | 0.210 |
Why?
|
| Bronchiolitis | 1 | 2023 | 8 | 0.210 |
Why?
|
| Bronchiolitis, Viral | 1 | 2023 | 9 | 0.210 |
Why?
|
| Bronchopneumonia | 1 | 2023 | 11 | 0.210 |
Why?
|
| Research Design | 2 | 2021 | 124 | 0.210 |
Why?
|
| Disinfectants | 1 | 2022 | 3 | 0.210 |
Why?
|
| Bacterial Infections | 1 | 2023 | 54 | 0.210 |
Why?
|
| Meningitis, Meningococcal | 1 | 2022 | 17 | 0.200 |
Why?
|
| Meningitis, Pneumococcal | 1 | 2022 | 20 | 0.200 |
Why?
|
| Anti-HIV Agents | 3 | 2017 | 1324 | 0.190 |
Why?
|
| Visitors to Patients | 1 | 2021 | 2 | 0.180 |
Why?
|
| Patient Isolation | 1 | 2021 | 5 | 0.180 |
Why?
|
| Syphilis, Congenital | 1 | 2021 | 13 | 0.180 |
Why?
|
| Syphilis | 1 | 2021 | 14 | 0.180 |
Why?
|
| Anti-Bacterial Agents | 3 | 2023 | 293 | 0.180 |
Why?
|
| Adenosine Monophosphate | 1 | 2020 | 5 | 0.180 |
Why?
|
| Drugs, Essential | 1 | 2020 | 4 | 0.180 |
Why?
|
| Dexamethasone | 1 | 2020 | 13 | 0.180 |
Why?
|
| Alanine | 1 | 2020 | 31 | 0.180 |
Why?
|
| Disease Notification | 1 | 2020 | 14 | 0.180 |
Why?
|
| Glucocorticoids | 1 | 2020 | 20 | 0.180 |
Why?
|
| Hospitals | 1 | 2021 | 103 | 0.180 |
Why?
|
| Policy Making | 1 | 2020 | 32 | 0.180 |
Why?
|
| Treatment Outcome | 5 | 2017 | 889 | 0.180 |
Why?
|
| Child Health | 1 | 2021 | 77 | 0.180 |
Why?
|
| Advisory Committees | 1 | 2020 | 14 | 0.170 |
Why?
|
| Antimicrobial Stewardship | 1 | 2020 | 14 | 0.170 |
Why?
|
| Vaccination | 3 | 2018 | 365 | 0.170 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2020 | 17 | 0.170 |
Why?
|
| Tuberculosis, Pulmonary | 2 | 2020 | 324 | 0.170 |
Why?
|
| Antiviral Agents | 1 | 2020 | 111 | 0.170 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 101 | 0.170 |
Why?
|
| Rubella Syndrome, Congenital | 1 | 2019 | 5 | 0.160 |
Why?
|
| Risk Factors | 6 | 2024 | 1475 | 0.160 |
Why?
|
| Influenza Vaccines | 1 | 2021 | 144 | 0.160 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2021 | 155 | 0.160 |
Why?
|
| Anti-Infective Agents | 1 | 2019 | 57 | 0.160 |
Why?
|
| Meningococcal Infections | 1 | 2019 | 24 | 0.160 |
Why?
|
| Adolescent | 6 | 2024 | 2985 | 0.160 |
Why?
|
| Feces | 1 | 2018 | 30 | 0.160 |
Why?
|
| Ethical Review | 1 | 2018 | 2 | 0.150 |
Why?
|
| Ethics Committees, Research | 1 | 2018 | 5 | 0.150 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2021 | 200 | 0.150 |
Why?
|
| Malnutrition | 1 | 2018 | 56 | 0.140 |
Why?
|
| Respiratory Tract Infections | 2 | 2024 | 266 | 0.140 |
Why?
|
| Databases, Factual | 1 | 2017 | 64 | 0.140 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2018 | 132 | 0.140 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2018 | 329 | 0.140 |
Why?
|
| Influenza, Human | 1 | 2021 | 374 | 0.140 |
Why?
|
| Case-Control Studies | 5 | 2017 | 480 | 0.140 |
Why?
|
| Sepsis | 1 | 2018 | 102 | 0.140 |
Why?
|
| Antibodies, Viral | 1 | 2019 | 284 | 0.140 |
Why?
|
| Incidence | 4 | 2019 | 685 | 0.130 |
Why?
|
| Pandemics | 3 | 2023 | 296 | 0.130 |
Why?
|
| Vaccines, Conjugate | 1 | 2017 | 171 | 0.130 |
Why?
|
| Antigens, Surface | 1 | 2015 | 11 | 0.130 |
Why?
|
| Bacterial Capsules | 1 | 2015 | 33 | 0.130 |
Why?
|
| Adult | 7 | 2023 | 5913 | 0.120 |
Why?
|
| Bacteremia | 1 | 2015 | 79 | 0.120 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2019 | 529 | 0.110 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 231 | 0.110 |
Why?
|
| Surveys and Questionnaires | 3 | 2022 | 563 | 0.110 |
Why?
|
| Dideoxynucleosides | 1 | 2013 | 29 | 0.110 |
Why?
|
| Retrospective Studies | 4 | 2019 | 799 | 0.100 |
Why?
|
| Time Factors | 3 | 2020 | 507 | 0.100 |
Why?
|
| Developing Countries | 3 | 2022 | 400 | 0.100 |
Why?
|
| Prevalence | 4 | 2018 | 1192 | 0.100 |
Why?
|
| Pertussis Vaccine | 2 | 2023 | 16 | 0.090 |
Why?
|
| Prospective Studies | 3 | 2019 | 1160 | 0.090 |
Why?
|
| Hospital Mortality | 2 | 2022 | 95 | 0.090 |
Why?
|
| Extensively Drug-Resistant Tuberculosis | 1 | 2010 | 20 | 0.090 |
Why?
|
| Pregnancy | 3 | 2021 | 1862 | 0.080 |
Why?
|
| Specimen Handling | 2 | 2018 | 105 | 0.070 |
Why?
|
| Nasopharynx | 2 | 2018 | 151 | 0.070 |
Why?
|
| Young Adult | 3 | 2019 | 2498 | 0.070 |
Why?
|
| Hydrops Fetalis | 1 | 2006 | 3 | 0.070 |
Why?
|
| Parvoviridae Infections | 1 | 2006 | 4 | 0.070 |
Why?
|
| Peritonitis | 1 | 2006 | 5 | 0.070 |
Why?
|
| Parvovirus B19, Human | 1 | 2006 | 5 | 0.070 |
Why?
|
| Infant, Premature, Diseases | 1 | 2006 | 19 | 0.070 |
Why?
|
| Cross-Sectional Studies | 3 | 2019 | 1422 | 0.070 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2019 | 198 | 0.060 |
Why?
|
| Africa South of the Sahara | 2 | 2017 | 353 | 0.060 |
Why?
|
| Oxygen | 1 | 2023 | 25 | 0.060 |
Why?
|
| Genomics | 1 | 2023 | 109 | 0.050 |
Why?
|
| Haemophilus influenzae | 1 | 2022 | 42 | 0.050 |
Why?
|
| Disease Progression | 1 | 2022 | 154 | 0.050 |
Why?
|
| Viral Load | 2 | 2017 | 819 | 0.050 |
Why?
|
| Syphilis Serodiagnosis | 1 | 2021 | 7 | 0.050 |
Why?
|
| Hospitals, Teaching | 1 | 2020 | 21 | 0.050 |
Why?
|
| Drug Resistance, Microbial | 1 | 2020 | 26 | 0.040 |
Why?
|
| Decision Making | 1 | 2020 | 53 | 0.040 |
Why?
|
| Cross Infection | 1 | 2020 | 52 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 2020 | 111 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 253 | 0.040 |
Why?
|
| Rubella virus | 1 | 2019 | 8 | 0.040 |
Why?
|
| Medical Records | 1 | 2019 | 23 | 0.040 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2019 | 135 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2020 | 325 | 0.040 |
Why?
|
| Global Health | 1 | 2019 | 193 | 0.040 |
Why?
|
| Mortality | 1 | 2019 | 104 | 0.040 |
Why?
|
| Asia, Southeastern | 1 | 2017 | 7 | 0.040 |
Why?
|
| Middle Aged | 2 | 2019 | 3601 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 385 | 0.030 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2021 | 472 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2019 | 321 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 163 | 0.030 |
Why?
|
| World Health Organization | 1 | 2017 | 137 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 133 | 0.030 |
Why?
|
| Logistic Models | 1 | 2017 | 254 | 0.030 |
Why?
|
| Fimbriae, Bacterial | 1 | 2015 | 10 | 0.030 |
Why?
|
| Adhesins, Bacterial | 1 | 2015 | 12 | 0.030 |
Why?
|
| Risk | 1 | 2015 | 87 | 0.030 |
Why?
|
| Morbidity | 1 | 2015 | 37 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2017 | 656 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2015 | 133 | 0.030 |
Why?
|
| Seroepidemiologic Studies | 1 | 2015 | 109 | 0.030 |
Why?
|
| Americas | 1 | 2014 | 10 | 0.030 |
Why?
|
| Aged | 1 | 2019 | 1740 | 0.030 |
Why?
|
| Microscopy | 1 | 2014 | 21 | 0.030 |
Why?
|
| Biomarkers | 1 | 2015 | 327 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2014 | 19 | 0.030 |
Why?
|
| Asia | 1 | 2014 | 72 | 0.030 |
Why?
|
| Health Status | 1 | 2015 | 111 | 0.030 |
Why?
|
| Sputum | 1 | 2014 | 135 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 411 | 0.030 |
Why?
|
| Poverty | 1 | 2014 | 152 | 0.030 |
Why?
|
| Mycobacterium | 1 | 2011 | 16 | 0.020 |
Why?
|
| Survival Rate | 1 | 2010 | 96 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2010 | 472 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2006 | 21 | 0.020 |
Why?
|
| Calcinosis | 1 | 2006 | 11 | 0.020 |
Why?
|
| Meconium | 1 | 2006 | 20 | 0.020 |
Why?
|
| Radiography | 1 | 2006 | 80 | 0.020 |
Why?
|
| Infant, Premature | 1 | 2006 | 56 | 0.020 |
Why?
|